In vivo and ex vivo, bevacizumab and other anti-VEGF inhibitors demonstrate regression of diabetic retinopathy sequelae, such as neovascularization, retinal non-perfusion, and diabetic macular edema. The gene discussed is VEGFA; the disease is diabetic retinopathy.